Table 2 AVATAR schedule of assessments
From: Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
|  | Baseline | Every 12 weeks |
|---|---|---|
Informed consent | X | Â |
Medical History | X | Â |
ECOG performance status | X | X |
CT chest, abdomen and pelvis or FDG PET/CT confirming oligoprogressive disease | X | Â |
Tumour Evaluation | Â | X |
Treatment-related toxicity assessment | Â | X |
Switching/cessation of systemic therapy | Â | X |
Further Stereotactic radiotherapy | Â | X |